초록 ▼

본 발명은 자궁경부암 환자의 분자표적 치료 반응성 예측용 유전자 마커 및 이의 용도에 관한 것으로, 보다 구체적으로 자궁경부암 환자에서 분자표적 치료에 대한 반응성 예측 용도 및 자궁경부암 예후 예측 용도에 관한 것이다. 본 발명자들은 70개 유전자를 자궁경부암에 대한 예후 유전자 시그니처로 확립하였고, 상기 유전자 시그니처와 임상병리학적 요인 간의 연관성을 확인하였으며 자궁경부암 환자군에서 본 발명에 따른 70개 유전자 시그니처를 이용해 분자표적 치료에 대한 반응성 예측의 유효성을 확인하였는바, 본 발명에 따른 70개 유전자 시그

본 발명은 자궁경부암 환자의 분자표적 치료 반응성 예측용 유전자 마커 및 이의 용도에 관한 것으로, 보다 구체적으로 자궁경부암 환자에서 분자표적 치료에 대한 반응성 예측 용도 및 자궁경부암 예후 예측 용도에 관한 것이다. 본 발명자들은 70개 유전자를 자궁경부암에 대한 예후 유전자 시그니처로 확립하였고, 상기 유전자 시그니처와 임상병리학적 요인 간의 연관성을 확인하였으며 자궁경부암 환자군에서 본 발명에 따른 70개 유전자 시그니처를 이용해 분자표적 치료에 대한 반응성 예측의 유효성을 확인하였는바, 본 발명에 따른 70개 유전자 시그니처는 실제 임상에서 자궁경부암 환자들의 예후를 예측하고 실제 분자표적 치료에 앞서 미리 반응성을 예측함으로써 보다 정확하고 효율적인 치료가 이루어지는데 유용하게 활용될 수 있을 것으로 기대된다.

대표청구항 ▼

ABCB7(ATP-binding cassette, sub-family B (MDR/TAP), member 7; GenBank 접근(accession) 번호: NM_004299.6, NM_001271696.3, NM_001271697.3, NM_001271698.3, NM_001271699.3), ARHGAP6(Rho GTPase activating protein 6; NM_013427.3, NM_006125.3, NM_013423.3, NM_001287242.2), ADD2(adducin 2 (beta); NM_001617.4, N

ABCB7(ATP-binding cassette, sub-family B (MDR/TAP), member 7; GenBank 접근(accession) 번호: NM_004299.6, NM_001271696.3, NM_001271697.3, NM_001271698.3, NM_001271699.3), ARHGAP6(Rho GTPase activating protein 6; NM_013427.3, NM_006125.3, NM_013423.3, NM_001287242.2), ADD2(adducin 2 (beta); NM_001617.4, NM_017482.4, NM_017488.4, NM_001185054.1, NM_001185055.2), ANXA13(annexin A13; NM_004306.4, NM_001003954.3), APLP1(amyloid beta (A4) precursor-like protein 1; NM_001024807.2, NM_005166.4), ATP5MC1(ATP synthase membrane subunit c locus 1; NM_005175.3, NM_001002027.2), ATP5MG(ATP synthase membrane subunit g; NM_006476.5), BAX(BCL2-associated X protein; NM_001291428.2, NM_001291429.2, NM_004324.4, NM_138761.4, NM_001291430.1, NM_004324.4, NM_138761.4, NM_001291430.1), BFSP2(beaded filament structural protein 2, phakinin; NM_003571.4), BTC(betacellulin; NM_001729.4, NM_001316963.2), BTN1A1(butyrophilin, subfamily 1, member A1; NM_001732.3), CALCA(calcitonin-related polypeptide alpha; NM_001741.3, NM_001033952.2, NM_001033953.2), CAMK4(calcium/calmodulin-dependent protein kinase IV; NM_001744.6, NM_001323374.2, NM_001323375.2, NM_001323376.2, NM_001323377.2), CDK5R2(cyclin-dependent kinase 5, regulatory subunit 2 (p39); NM_003936), CHST7(carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7; NM_019886.4), CLGN(calmegin; NM_004362.3, NM_001130675.1), COL19A1(collagen, type XIX, alpha 1; NM_001858.6), CPLX2(complexin 2; NM_006650.4, NM_001008220.2), CRTAP(cartilage associated protein; NM_006371.5), CX3CL1(chemokine (C-X3-C motif) ligand 1; NM_002996.6), CXCL12(chemokine (C-X-C motif) ligand 12; NM_199168.4, NM_000609.7, NM_001033886.2, NM_001178134.2, NM_001277990.2), CXXC4(CXXC finger protein 4; NM_025212.4), DDX25(DEAD (Asp-Glu-Ala-Asp) box helicase 25; NM_013264.5, NM_001330438.2), DIAPH3(diaphanous-related formin 3; NM_001042517.2, NM_030932.3, NM_001258366.2, NM_001258367.2, NM_001258368.2, NM_001258369.1, NM_001258370.2), DNM2(dynamin 2; NM_001005360.2, NM_001005361.2, NM_004945.3, NM_001005362.2, NM_001190716.2), EIF4E(eukaryotic translation initiation factor 4E; NM_001968.4, NM_001130679.2, NM_001130678.3, NM_001331017.1), ESM1(endothelial cell-specific molecule 1; NM_007036.5, NM_001135604.2), FFAR3(Free fatty acid receptor 3; NM_005304.5), FGFR2(fibroblast growth factor receptor 2; NM_000141.4, NM_022970.3, NM_001144913.1, NM_001144914.1, NM_001144915.1, NM_001144916.1, NM_001144917.2, NM_001144918.2, NM_001144919.2, NM_023029.2, NM_001320654.1, NM_001320658.2), GHR(growth hormone receptor; NM_001242399.2, NM_001242400.2, NM_001242401.4, NM_001242402.2, NM_001242403.2, NM_001242404.2, NM_001242405.2, NM_001242406.2, NM_001242460.1, NM_001242462.1), GHRHR(growth hormone releasing hormone receptor; NM_000823.4), GRB2(growth factor receptor-bound protein 2; NM_002086.5, NM_203506.2), HAPLN1(hyaluronan and proteoglycan link protein 1; NM_001884.4), HTATSF1(HIV-1 Tat specific factor 1; NM_001163280.1, NM_014500.5), INSL4(insulin-like 4 (placenta); NM_002195.2), KCNAB1(potassium voltage-gated channel, shaker-related subfamily, beta member 1; NM_172160.2, NM_003471.3, NM_172159.3, NM_001308217.1, NM_001308222.1), KCNH6(potassium voltage-gated channel, subfamily H (eag-related), member 6; NM_030779.4, NM_173092.3, NM_001278919.2, NM_001278920.2), KDSR(3-ketodihydrosphingosine reductase; NM_002035.4), LAMP2(lysosomal-associated membrane protein 2; NM_002294.3, NM_013995.2, NM_001122606.1), LETM1(leucine zipper-EF-hand containing transmembrane protein 1; NM_012318.3), MAPK8IP2(mitogen-activated protein kinase 8 interacting protein 2; NM_012324.6), MFAP2(microfibrillar-associated protein 2; NM_017459.2, NM_002403.4, NM_001135247.1, NM_001135248.1), MGAT4B(mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B; NM_014275.5, NM_054013.3), MYLIP(myosin regulatory light chain interacting protein; NM_013262.4), NCAN(neurocan; NM_004386.3), NCOA1(nuclear receptor coactivator 1; NM_003743.5, NM_147223.3, NM_147233.2, NM_001362950.1, NM_001362952.1, NM_001362954.1, NM_001362955.1), NIBAN1(Nihban apoptosis regulator1; NM_052966.4), NSG2(neuronal vesicle trafficking associated 2; NM_015980), NTRK2(neurotrophic tyrosine kinase, receptor, type 2; NM_006180.5, NM_001007097.3, NM_001018064.3, NM_001018065.2, NM_001018066.3), OMP(olfactory marker protein; NM_006189), OXCT1(3-oxoacid CoA transferase 1; NM_001364299.2, NM_001364300.2, NM_000436.4, NM_001364301.2, NM_001364302.2, NM_001364303.1), PAFAH1B2(platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa); NM_002572.4, NM_001184746.2, NM_001184747.2, NM_001184748.1, NM_001309431.2), PCDHB6(protocadherin beta 6; NM_018939.3, NM_001303145.2), PEX16(peroxisomal biogenesis factor 16; NM_004813.3, NM_057174.2), PPP2R1B(protein phosphatase 2, regulatory subunit A, beta; NM_002716.5, NM_181699.3, NM_181700.2, NM_001177562.2, NM_001177563.2), PTP4A1(protein tyrosine phosphatase type IVA, member 1; NM_003463.4), RAD51C(RAD51 paralog C; NM_058216.3, NM_002876.3), RBP4(retinol binding protein 4, plasma; NM_006744.4, NM_001323517.1, NM_001323518.1), SCAMP3(secretory carrier membrane protein 3; NM_005698.4, NM_052837.3), SCRT1(scratch family zinc finger 1; NM_031309.6), SERPINF1(serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1; NM_002615.7, NM_001329903.1, NM_001329904.1, NM_001329905.1), SLIT1(slit homolog 1 (Drosophila); NM_003061.3), SOD3(superoxide dismutase 3, extracellular; NM_003102.4), STAT5A(signal transducer and activator of transcription 5A; NM_001288718.1, NM_003152.3, NM_001288719.1, NM_001288720.1), TGFBRAP1(transforming growth factor, beta receptor associated protein 1; NM_004257.6, NM_001142621.3, NM_001328646.2), TLK2(tousled-like kinase 2; NM_006852.4, NM_001284333.2, NM_001284363.1, NM_001330418.2), TYMS(thymidylate synthetase; NM_001071.4, NM_001354867.2, NM_001354868.2), VCP(valosin containing protein; NM_007126.5, NM_001354927.1, NM_001354928.), YWHAZ(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta; NM_003406.4, NM_145690.3, NM_001135699.1, NM_001135700.2, NM_001135701.2, NM_001135702.2), 및 ZBTB16(zinc finger and BTB domain containing 16; NM_006006.6, NM_001018011.2, NM_001354750.2, NM_001354751.2, NM_001354752.1)으로 이루어진 군에서 선택되는 하나 이상의 유전자의 mRNA 또는 상기 유전자가 암호화하는 단백질 수준을 측정하는 제제를 포함하는, 자궁경부암 환자의 분자표적 치료 반응성 예측용 조성물.